Palisade Bio, Inc. (PALI) Reports In-Line Q3 EPS

Palisade Bio, Inc. (NASDAQ: PALI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Palisade Bio, Inc. (PALI) click here.

You May Also Be Interested In

• Truist Financial Corp. (TFC) Tops Q2 EPS by 15c
• Washington Federal (WAFD) Misses Q3 EPS by 1c
• UBS sees 10% upside for global stocks through mid 2027